Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.57 |
| ▸ | LPL | P06858 | 12/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2588010 | 0.98 | FFAR1 (0.59) | FFAR1LPLLIPGDGAT1IRAK4 | |
| SCHEMBL19861553 | 0.85 | FFAR1 (0.56) | FFAR1LPLLIPGDGAT1IRAK4 | |
| SCHEMBL2752557 | 0.83 | FFAR1 (0.54) | FFAR1LPLLIPGDGAT1IRAK4 | |
| SCHEMBL19524038 | 0.83 | FFAR1 (0.61) | FFAR1LPLLIPGDGAT1IRAK4 | |
| SCHEMBL19540284 | 0.83 | FFAR1 (0.54) | FFAR1LPLLIPGDGAT1IRAK4 | |
| SCHEMBL17904530 | 0.83 | FFAR1 (0.57) | FFAR1LPLLIPGDGAT1IRAK4 | |
| SCHEMBL13412137 | 0.81 | FFAR1 (0.59) | FFAR1LPLLIPGDGAT1IRAK4 | |
| SCHEMBL14746347 | 0.81 | FFAR1 (0.56) | FFAR1LPLLIPGDGAT1IRAK4 | |
| SCHEMBL18781460 | 0.81 | FFAR1 (0.52) | FFAR1LPLLIPGDGAT1IRAK4 | |
| SCHEMBL17103727 | 0.81 | FFAR1 (0.56) | FFAR1LPLLIPGDGAT1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116870-A1 | NOVEL NAV 1.1 POTENTIATORS | BOEHRINGER INGELHEIM INT (DE) | 2026-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116870-A1 | NOVEL NAV 1.1 POTENTIATORS | SCN1B, SCN1A, CACNA1B | FFAR1 3147/4885LPL 3067/4885LIPG 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.